Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196822 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL28583726 | 0.89 | HSD17B10 (0.76) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL11458656 | 0.89 | HSD17B10 (0.76) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL1344559 | 0.89 | HSD17B10 (0.76) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL11441141 | 0.89 | HSD17B10 (0.76) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL2744431 | 0.86 | MAOB (0.70) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL2744424 | 0.86 | MAOB (0.70) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL4745288 | 0.85 | KDM4E (0.81) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL4745286 | 0.85 | KDM4E (0.81) | KDM4EALDH1A1CYP1A2HSD17B10MAOB | |
| SCHEMBL79427 | 0.85 | KDM4E (0.81) | KDM4EALDH1A1CYP1A2HSD17B10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015129755-A1 | NOVEL COMPOUND AND TEXTURE IMPROVER CONTAINING SAID COMPOUND | 味の素株式会社 | 2015-09-03 | — | — | WO | disclosed |
| US-20120213702-A1 | NOVEL DIAGNOSTIC AGENTS FOR THE NON-INVASIVE IN VIVO IMAGING OF AMINOPEPTIDASE N (APN/CD13) | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120094973-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-04-19 | — | — | US | disclosed |
| US-8088818-B2 | Catechol-based derivatives for treating or preventing diabetics | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-01-03 | — | — | US | disclosed |
| US-20110224260-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20090143397-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | LOTUS PHARMACEUTICAL CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| EP-1622896-B1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-7205326-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205325-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| EP-1622896-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1613623-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | disclosed |
| WO-2004085434-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209933-A1 | Oxazole derivatives | OXA1L, SULT1E1, CYP3A7 | KDM4E 2258/4885ALDH1A1 24/4885CYP1A2 23/4885 |
| US-20120213702-A1 | NOVEL DIAGNOSTIC AGENTS FOR THE NON-INVASIVE IN VIVO IMAGING OF AMINOPEPTIDASE N (APN/CD13) | ANPEP, DPP3, NEU3 | KDM4E 2213/4885ALDH1A1 1140/4885CYP1A2 2666/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885ALDH1A1 2549/4885CYP1A2 375/4885 |
| US-20120094973-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A8 | KDM4E 3568/4885ALDH1A1 380/4885CYP1A2 1966/4885 |
| US-20110224260-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A8 | KDM4E 3568/4885ALDH1A1 380/4885CYP1A2 1966/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885ALDH1A1 2549/4885CYP1A2 375/4885 |
| US-20090143397-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A3 | KDM4E 3487/4885ALDH1A1 391/4885CYP1A2 1905/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | KDM4E 1358/4885ALDH1A1 2482/4885CYP1A2 362/4885 |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | ERBB2, EGFR, ERBB3 | KDM4E 3886/4885ALDH1A1 323/4885CYP1A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.